The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Postexposure Protection of Guinea Pigs against a Lethal Ebola Virus Challenge Is Conferred by RNA Interference
Open accessAbstract
BACKGROUND: Ebola virus (EBOV) infection causes a frequently fatal hemorrhagic fever (HF) that is refractory to treatment with currently available antiviral therapeutics. RNA interference represents a powerful, naturally occurring biological strategy for the inhibition of gene expression and has demonstrated utility in the inhibition of viral replication. Here, we describe the development of a potential therapy for EBOV infection that is based on small interfering RNAs (siRNAs). METHODS: Four siRNAs targeting the polymerase (L) gene of the Zaire species of EBOV (ZEBOV) were either complexed with polyethylenimine (PEI) or formulated in stable nucleic acid-lipid particles (SNALPs). Guinea pigs were treated with these siRNAs either before or after lethal ZEBOV challenge. RESULTS: Treatment of guinea pigs with a pool of the L gene-specific siRNAs delivered by PEI polyplexes reduced plasma viremia levels and partially protected the animals from death when administered shortly before the ZEBOV challenge. Evaluation of the same pool of siRNAs delivered using SNALPs proved that this system was more efficacious, as it completely protected guinea pigs against viremia and death when administered shortly after the ZEBOV challenge. Additional experiments showed that 1 of the 4 siRNAs alone could completely protect guinea pigs from a lethal ZEBOV challenge. CONCLUSIONS: Further development of this technology has the potential to yield effective treatments for EBOV HF as well as for diseases caused by other agents that are considered to be biological threats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Guide for the care and use of laboratory animals
(1997) · Choice Reviews Online · doi:10.5860/choice.34-3310 · Cited by 2,922
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Self-citationHornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Self-citationRNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
RNA interference in adult mice
McCaffrey, A. P., Meuse, L., Pham, T.-T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A. (2002) · Nature · doi:10.1038/418038a · Cited by 1,059
Catastrophic ape decline in western equatorial Africa
Walsh, P. D., Abernethy, K. A., Bermejo, M., Beyers, R., De Wachter, P., Akou, M. E., Huijbregts, B., Mambounga, D. I., Toham, A. K., Kilbourn, A. M., et al. (2003) · Nature · doi:10.1038/nature01566 · Cited by 681
Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus Macaques
Geisbert, T. W., Hensley, L. E., Larsen, T., Young, H. A., Reed, D. S., Geisbert, J. B., Scott, D. P., Kagan, E., Jahrling, P. B., & Davis, K. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63591-2 · Cited by 576
Self-citationCationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Self-citationA Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., & Huggins, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515386 · Cited by 492
Self-citationInhibition of influenza virus production in virus-infected mice by RNA interference
Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H. N., & Chen, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402486101 · Cited by 444
Emeny, J. M., & Morgan, M. J. (1979) · Journal of General Virology · doi:10.1099/0022-1317-43-1-247 · Cited by 440
Geisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., & Vlasuk, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15012-x · Cited by 382
Self-citationSanchez, A., Kiley, M. P., Holloway, B. P., & Auperin, D. D. (1993) · Virus Research · doi:10.1016/0168-1702(93)90063-s · Cited by 318
Pathogenesis of Experimental Ebola Virus Infection in Guinea Pigs
Connolly, B. M., Steele, K. E., Davis, K. J., Geisbert, T. W., Kell, W. M., Jaax, N. K., & Jahrling, P. B. (1999) · The Journal of Infectious Diseases · doi:10.1086/514305 · Cited by 308
Self-citationA Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA
Jeffs, L. B., Palmer, L. R., Ambegia, E. G., Giesbrecht, C., Ewanick, S., & MacLachlan, I. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1873-z · Cited by 307
Self-citationSmall interfering RNA Inhibits Hepatitis B virus replication in mice
Giladi, H., Ketzinel-Gilad, M., Rivkin, L., Felig, Y., Nussbaum, O., & Galun, E. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00244-2 · Cited by 306
Spann, K. M., Tran, K. C., & Collins, P. L. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5353-5362.2005 · Cited by 283
Jahrling, P. B., Geisbert, T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., & Peters, C. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/514310 · Cited by 269
Self-citationMarburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates
Hevey, M., Negley, D., Pushko, P., Smith, J., & Schmaljohn, A. (1998) · Virology · doi:10.1006/viro.1998.9367 · Cited by 262
Evaluation in Nonhuman Primates of Vaccines against Ebola Virus
Geisbert, T. W., Pushko, P., Anderson, K., Smith, J., Davis, K. J., & Jahrling, P. B. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0805.010284 · Cited by 248
Self-citationMosca, J. D., & Pitha, P. M. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.6.2279 · Cited by 208
Parren, P. W. H. I., Geisbert, T. W., Maruyama, T., Jahrling, P. B., & Burton, D. R. (2002) · Journal of Virology · doi:10.1128/jvi.76.12.6408-6412.2002 · Cited by 204
Self-citationBray, M., Hatfill, S. J., Hensley, L. E., & Huggins, J. W. (2001) · Journal of Comparative Pathology · doi:10.1053/jcpa.2001.0503 · Cited by 156
Self-citationInhibition of SARS-CoV replication by siRNA
Wu, C., Huang, H.-W., Liu, C.-Y., Hong, C.-F., & Chan, Y.-L. (2004) · Antiviral Research · doi:10.1016/j.antiviral.2004.09.005 · Cited by 153
A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. S., & Huggins, J. W. (1999) · The Journal of Infectious Diseases · doi:10.1086/514292 · Cited by 153
Self-citationEbola virus haemorrhagic fever
Pattyn, S. R. (1978) · Cited by 141
Nishikawa, M., Yamauchi, M., Morimoto, K., Ishida, E., Takakura, Y., & Hashida, M. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301140 · Cited by 139
RNAi, a new therapeutic strategy against viral infection
TAN, F. L., & Yin, J. Q. (2004) · Cell Research · doi:10.1038/sj.cr.7290248 · Cited by 124
Huggins, J., Zhang, Z., & Bray, M. (1999) · The Journal of Infectious Diseases · doi:10.1086/514316 · Cited by 116
3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice
Bray, M., Raymond, J. L., Geisbert, T. W., & Baker, R. O. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00018-9 · Cited by 103
Self-citationBiological stability of [3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat
Stein, Y., Halperin, G., & Stein, O. T. (1980) · FEBS Letters · doi:10.1016/0014-5793(80)80771-x · Cited by 87
Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo
Biessen, E. A. L., Vietsch, H., Rump, E. T., Fluiter, K., Kuiper, J., Bijsterbosch, M. K., & van Berkel, T. J. C. (1999) · Biochemical Journal · doi:10.1042/bj3400783 · Cited by 82
[3] Stabilized plasmid-lipid particles: A systemic gene therapy vector
Fenske, D. B., MacLachlan, I., & Cullis, P. R. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)46048-x · Cited by 72
Self-citationCollard, W. T., Yang, Y., Kwok, K. Y., Park, Y., & Rice, K. G. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200004)89:4<499::aid-jps7>3.0.co;2-v · Cited by 72
Silencing viruses by RNA interference
Colbère-Garapin, F., Blondel, B., Saulnier, A., Pelletier, I., & Labadie, K. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.02.003 · Cited by 42
Sánchez, A. B., Perez, M., Cornu, T. I., & de la Torre, J. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11071-11081.2005 · Cited by 40
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Cited by 21
Cited by
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Self-citationInterfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Metadata
- Authors
- Geisbert, T. W., Hensley, L. E., Kagan, E., Yu, E. Z., Geisbert, J. B., Daddario‐DiCaprio, K., Fritz, E. A., Jahrling, P. B., McClintock, K., Phelps, J. R., Lee, A. C. H., Judge, A., Jeffs, L. B., & MacLachlan, I.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06-15
- Volume
- 193
- Issue
- 12
- Pages
- 1650-1657
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2105364677
- Cited by
- 254
- References
- 40
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.